These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 38061213)

  • 41. Hospital volume and outcome in rectal cancer patients; results of a population-based study in the Netherlands.
    Hagemans JAW; Alberda WJ; Verstegen M; de Wilt JHW; Verhoef C; Elferink MA; Burger JWA
    Eur J Surg Oncol; 2019 Apr; 45(4):613-619. PubMed ID: 30600101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis.
    Xu Z; Mohile SG; Tejani MA; Becerra AZ; Probst CP; Aquina CT; Hensley BJ; Arsalanizadeh R; Noyes K; Monson JR; Fleming FJ
    Cancer; 2017 Jan; 123(1):52-61. PubMed ID: 27560162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MRI-defined high-risk rectal cancer patients: outcome comparison between neoadjuvant chemoradiotherapy plus TME and TME plus adjuvant chemotherapy or TME alone.
    Jia X; Xie P; Bi L; Meng X; Wang Z; Hong N; Wang Y
    Br J Radiol; 2021 Apr; 94(1120):20201221. PubMed ID: 33591799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study.
    Sorrentino L; Guaglio M; Battaglia L; Bonfanti G; Vitellaro M; Bianchi AC; Milione M; Belli F
    Int J Colorectal Dis; 2019 Dec; 34(12):2161-2169. PubMed ID: 31741026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early local recurrence and one-year mortality of rectal cancer after restricting the neoadjuvant therapy regime.
    Tersteeg JJC; van Esch LM; Gobardhan PD; Kint PAM; Rozema T; Crolla RMPH; Schreinemakers JMJ
    Eur J Surg Oncol; 2019 Apr; 45(4):597-605. PubMed ID: 30583821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of adjuvant chemotherapy on patients with ypT0-2 ypN0 rectal cancer after neoadjuvant chemoradiation: a cohort study from a tertiary referral hospital.
    Galata C; Merx K; Mai S; Gaiser T; Wenz F; Post S; Kienle P; Hofheinz RD; Horisberger K
    World J Surg Oncol; 2018 Aug; 16(1):156. PubMed ID: 30071852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.
    Vriens BEPJ; Keymeulen KBMI; Kroep JR; Charehbili A; Peer PG; de Boer M; Aarts MJB; Heuts EM; Tjan-Heijnen VCG;
    Oncotarget; 2017 Jul; 8(28):46557-46564. PubMed ID: 28177921
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 50. Neoadjuvant therapy does not affect lymph node ratio in rectal cancer.
    Chang KH; Kelly NP; Duff GP; Condon ET; Waldron D; Coffey JC
    Surgeon; 2016 Oct; 14(5):270-3. PubMed ID: 26148760
    [TBL] [Abstract][Full Text] [Related]  

  • 51. lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.
    Kim YS; Kim JH; Yoon SM; Choi EK; Ahn SD; Lee SW; Kim JC; Yu CS; Kim HC; Kim TW; Chang HM
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):796-802. PubMed ID: 19289261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy.
    Leibold T; Shia J; Ruo L; Minsky BD; Akhurst T; Gollub MJ; Ginsberg MS; Larson S; Riedel E; Wong WD; Guillem JG
    J Clin Oncol; 2008 May; 26(13):2106-11. PubMed ID: 18362367
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic review and meta-analysis of long-term oncological outcomes of lateral lymph node dissection for metastatic nodes after neoadjuvant chemoradiotherapy in rectal cancer.
    Kroon HM; Hoogervorst LA; Hanna-Rivero N; Traeger L; Dudi-Venkata NN; Bedrikovetski S; Kusters M; Chang GJ; Thomas ML; Sammour T
    Eur J Surg Oncol; 2022 Jul; 48(7):1475-1482. PubMed ID: 35568607
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
    Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
    Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis.
    Chen WW; Wang WL; Dong HM; Wang G; Li XK; Li GD; Chen WH; Chen J; Bai SX
    World J Surg Oncol; 2022 Apr; 20(1):119. PubMed ID: 35413852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparison on efficacy between fascia-oriented versus vascular-oriented lateral lymph node dissection in patients with rectal cancer].
    Wang ZJ; Liu Z; Liang JW; Zhang MG; Mei SW; Shen HY; Chen JN; Li J; Zhao FQ; Wei FZ; Xiao TX; Liu Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Jul; 24(7):611-618. PubMed ID: 34289546
    [No Abstract]   [Full Text] [Related]  

  • 57. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
    JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant chemotherapy and radiotherapy followed by resection/ablation in stage IV rectal cancer patients with potentially resectable metastases.
    Li R; Wang Q; Zhang B; Yuan Y; Xie W; Huang X; Zhou C; Zhang S; Niu S; Chang H; Chen D; Miao H; Zeng ZF; Xiao W; Gao Y
    BMC Cancer; 2021 Dec; 21(1):1333. PubMed ID: 34906114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
    Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
    Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.
    Kim CG; Ahn JB; Shin SJ; Beom SH; Heo SJ; Park HS; Kim JH; Choe EA; Koom WS; Hur H; Min BS; Kim NK; Kim H; Kim C; Jung I; Jung M
    BMC Cancer; 2017 Sep; 17(1):615. PubMed ID: 28865435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.